loading
Precedente Chiudi:
$8.98
Aprire:
$9.28
Volume 24 ore:
2.32M
Relative Volume:
2.20
Capitalizzazione di mercato:
$737.75M
Reddito:
-
Utile/perdita netta:
$-209.96M
Rapporto P/E:
-3.0285
EPS:
-3.16
Flusso di cassa netto:
$-176.27M
1 W Prestazione:
+14.61%
1M Prestazione:
-4.40%
6M Prestazione:
-29.37%
1 anno Prestazione:
+81.59%
Intervallo 1D:
Value
$9.21
$10.16
Intervallo di 1 settimana:
Value
$8.25
$10.16
Portata 52W:
Value
$4.93
$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name
Nome
Replimune Group Inc
Name
Telefono
(781) 222-9600
Name
Indirizzo
500 UNICORN PARK, WOBURN, MA
Name
Dipendente
479
Name
Cinguettio
@Replimune
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
REPL's Discussions on Twitter

Confronta REPL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
REPL
Replimune Group Inc
9.57 649.07M 0 -209.96M -176.27M -3.16
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-28 Iniziato ROTH MKM Buy
2023-04-17 Ripresa Piper Sandler Overweight
2021-11-19 Iniziato Piper Sandler Overweight
2021-10-15 Ripresa BTIG Research Buy
2020-11-17 Iniziato BTIG Research Buy
2020-11-02 Iniziato Jefferies Buy
2020-10-15 Aggiornamento H.C. Wainwright Neutral → Buy
2020-07-01 Downgrade H.C. Wainwright Buy → Neutral
2020-05-05 Iniziato Barclays Overweight
2019-09-04 Iniziato ROTH Capital Buy
2019-07-23 Iniziato Chardan Capital Markets Buy
2019-07-12 Aggiornamento JP Morgan Neutral → Overweight
2019-07-08 Iniziato H.C. Wainwright Buy
2019-04-25 Iniziato Wedbush Outperform
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-08-14 Iniziato JP Morgan Overweight
2018-08-14 Iniziato Leerink Partners Outperform
Mostra tutto

Replimune Group Inc Borsa (REPL) Ultime notizie

pulisher
02:50 AM

Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00 at Piper Sandler - Defense World

02:50 AM
pulisher
Jun 02, 2025

Piper Sandler raises Replimune stock price target after updates - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Does Replimune Group Inc (NASDAQ: REPL) Still Need To Convince Analysts? - Stocksregister

Jun 02, 2025
pulisher
Jun 02, 2025

Replimune Group (REPL) Price Target Raised by Piper Sandler Analyst | REPL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Piper Sandler raises Replimune stock price target after updates By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Replimune (REPL) Price Target Raised by Piper Sandler Amid Positive Developments | REPL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BNP Paribas Financial Markets Trims Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Presents New Analyses from the IGNYTE Study of RP1 plu - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile - Nasdaq

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed ... - Enidnews.com

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma Trial | REPL Stock News - Stock Titan

Jun 01, 2025
pulisher
Jun 01, 2025

ProShare Advisors LLC Grows Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Group (NASDAQ:REPL) Trading Down 5.9% – Time to Sell? - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 31, 2025
pulisher
May 29, 2025

Replimune to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC - Defense World

May 29, 2025
pulisher
May 28, 2025

Why Okta Stock Plunged on Wednesday - The Globe and Mail

May 28, 2025
pulisher
May 26, 2025

HC Wainwright Estimates Replimune Group Q3 Earnings - Defense World

May 26, 2025
pulisher
May 26, 2025

Leerink Partnrs Estimates Replimune Group Q1 Earnings - Defense World

May 26, 2025
pulisher
May 24, 2025

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review - Investing.com India

May 24, 2025
pulisher
May 24, 2025

Barclays Remains a Buy on Replimune Group (REPL) - The Globe and Mail

May 24, 2025
pulisher
May 23, 2025

Replimune director sells $260,168 in common stock By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Replimune (REPL) Plans Major Stock Sale with 25.1M Shares Offeri - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Replimune Group Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Replimune (REPL) Announces $250 Million Securities Shelf Filing | REPL Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Replimune Group, Inc. (REPL) Stock Analysis: An Insight into a Biotech Gem with 141% Upside Potential - DirectorsTalk Interviews

May 23, 2025
pulisher
May 23, 2025

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Stock Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - Defense World

May 23, 2025
pulisher
May 23, 2025

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Replimune director sells $260,168 in common stock - Investing.com Australia

May 23, 2025
pulisher
May 23, 2025

Replimune Group Advances Oncolytic Immunotherapy Pipeline - TipRanks

May 23, 2025
pulisher
May 22, 2025

Replimune’s chief commercial officer sells $30,179 in stock By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Replimune Group, Inc. SEC 10-K Report - TradingView

May 22, 2025
pulisher
May 22, 2025

REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Replimune (REPL) Prepares for Landmark Melanoma Treatment Launch - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Replimune Group Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 22, 2025
pulisher
May 22, 2025

Transcript : Replimune Group, Inc., Q4 2025 Earnings Call, May 22, 2025 - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025 - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides ... - Bluefield Daily Telegraph

May 22, 2025
pulisher
May 22, 2025

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - TradingView

May 22, 2025
pulisher
May 20, 2025

Northern Trust Corp Acquires 40,134 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

May 20, 2025
pulisher
May 18, 2025

Replimune Group (NASDAQ:REPL) Stock Price Up 10.9% – What’s Next? - Defense World

May 18, 2025
pulisher
May 16, 2025

Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha

May 16, 2025
pulisher
May 16, 2025

Replimune Announces Dates for Fiscal Fourth Quarter and Year End - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - The Manila Times

May 16, 2025
pulisher
May 16, 2025

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and - Bluefield Daily Telegraph

May 16, 2025

Replimune Group Inc Azioni (REPL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Capitalizzazione:     |  Volume (24 ore):